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Apoptosis and proliferation in thyroid carcinoma:
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Summary The aim of this study was to determine the apoptotic cell death in 92 thyroid carcinomas of different histotypes (42 papillary, PTC;
12 poorly differentiated, PDC; 21 undifferentiated, UC; and 17 medullary, MC) by terminal deoxynucleotidyl transferase (TdT)-mediated
dUTP-digoxigenin nick end labelling (TUNEL). Apoptotic index (Al, evaluated as a percentage ofTUNEL-positive cells of neoplasticcells) was
calculated in each tumour. The Al was very low in all subtypes of thyroid carcinoma, ranging from a median value of 0.2 in PTC to 1.4 in UC.
The proliferative activity was determined by immunohistochemistry using monoclonal antibody, MIB-1. The percentage of proliferating cells
was significantly different among the histotypes, increasing with tumour aggressiveness (from the mean value of 3.1 for PTC to 5.6 for PDC
and 51.8 for UC). In addition, the ratio between proliferative activity and apoptosis was significantly higher in UC than in the other histotypes.
The expression of bcl-2 and p53 protein (important in the modulation of cell death) was correlated (bcl-2, inverse correlation, r2 = 0.1, P=
0.04; p53, direct correlation, r2= 0.11, P= 0.02) with apoptotic index in PTC.
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Cell numbers are regulated by a balance between proliferation,
growth arrest and programmed cell death (apoptosis, PCD). Until
recently, the majority of the studies on oncogenesis have focused
on the regulation of cell proliferation. The finding that alterations
ofnegative growth control, including growth arrest and PCD,play
a key role in the development of human cancer has been demon-
strated by the explosion of reports in this field (Barr and Tomei,
1994; Canman and Kastan, 1995; Katsikis and Leben, 1995;
Salomon andDiaz-Cano, 1995; Stauton andGaffeney, 1995). PCD
is an active cellular process involved in a variety ofphysiological
events in which rapid elimination ofunwanted cells must occur. Its
importance in the turnover of self-renewing tissues, morphogen-
esis, embryonic development, maturation of cells of the immune
system, as well as in the development ofcancer and otherpatholo-
gies, is increasingly being recognized (Chandler et al, 1994;
Cotman and Anderson, 1995; Isner et al, 1995; Osborne, 1995).
Apoptotic cells can be identified both by nuclear morphology and
by techniques that detect fragmentated DNA. The latter method-
ology could be applied for the in situ visualization ofapoptosis by
specific labelling of DNA fragmentation. By using Gavrieli's
method (Gavrieli et al, 1992), apoptosis can be detected at single-
cell level in formalin-fixed, paraffin-embedded tissue sections,
thereby allowing the study ofretrospective cases.
In the present study, we analysed apoptosis in thyroid carci-
noma, focusing on its association with the proliferation rate of the
tumours themselves. In addition, since apoptosis can be regulated
by thep53 tumour-suppressor gene and by bcl-2, we analysed the
p53 and bcl-2 expression on the tumour.
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MATERIALS AND METHODS
Patients and follow up
The study was carried out on 92 patients with primary malignant
thyroid tumours. The histological diagnoses of the tumours,
according to WHO (Hedinger, 1988) and subsequent updating
(Sakamoto et al, 1983; Rosai et al, 1990; Johnson et al; 1992;
Sobrinho-Simoes, 1995) were as follows: 42 PTC, 12 PDC, 21 UC
and 17 MC. The PTCs consisted ofthe following variants according
to WHO: 12 follicular and 30 not otherwise specified. The 12 PDC
were represented by five insular carcinomas, five oxyphilic carci-
nomas and two trabecular carcinomas. This series of thyroid
tumours is part of a larger series ofthyroid cancer patients followed
at the Institute of Endocrinology, which is a referral centre for
thyroid carcinomas in Italy. We studied all patients who received
primary surgical treatment at the University of Pisa and whose
tissues were available at the Department ofPathology.
Initial treatment was total (near-total) thyroidectomy in all
patients, regardless of the histotype. Lymph node dissection was
performed on principle in MC,but not in PTC, in which lymph node
dissection was performed only in the case ofevident node involve-
ment. Post-surgical treatment included '13I therapy for PTC and
PDC [if iodine uptake of whole body scan (WBS) with 1311 was
demonstrated] followed by L-thyroxine suppressive therapy. MC
and PDC (with no iodine uptake) were treated with chemotherapy
and/or radiotherapy in case of recurrence or distant metastases. UC
were treated with total thyroidectomy whenever possible, followed
by external radiotherapy and/or chemotherapy. All patients were
regularly followed up by physical examination, chest radiograph
and WBS with 1311 (PTC).
Analysis of programmed cell death by the terminal
transferase assay
Paraffin-embedded sections of thyroid tumours were deparaf-
finized in xylene twice for 5 min and then rehydrated in 100%,
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95%, 75% and 50% ethanol for 3 min each. After rehydration,
sections were washed in phosphate-buffered saline (PBS)
containing 0.5% hydrogen peroxide to inactivate endogenous
peroxidase, and then incubated with 20 jg ml-' proteinase K in
PBS. DNA fragments in the tissue section were determined
using ApopTag Plus in situ apoptosis detection kit (Oncor,
Gaithersburg, MD, USA). The labelling procedure was performed
following the supplier's instructions. Briefly, the enzyme, terminal
deoxynucleotidyl tranferase (TdT), which catalyses a template-
independent addition of deoxyribonucleotide to 3'-OH ends of
DNA, was used to incorporate digoxigenin-conjugated dUTP
to the ends of DNA fragments. The signal of TdT-mediated
dUTP nick end labelling (TUNEL) was than detected by an
anti-digoxigenin antibody conjugated with peroxidase, a reported
enzyme that catalytically generates a brown-coloured product
from the chromogenic substrate, diaminobenzidine. The labelling
conditions were optimized by adjusting incubation time and
concentrations of TdT. After TUNEL, counterstaining was
performed by immersing the slides in 0.5% methyl green in
0.1 mol 1-1 sodium acetate solution (pH 4.0) for 5 min at room
temperature. The slides were washed, dried and mounted in
Permount medium. Cell counting was performed with a light
microscope. For each slide, 1000 cells were counted in random
fields of each section at high power. The cells with clear nuclear
labelling were defined as TUNEL-positive cells. Since apoptotic
cells were often identified in the compromised rim of necrotic
zones, such areas were not included in assessing AI. As positive
control, sections of normal colonic mucosa or lymph node were
used. The apoptotic index was calculated as percentage of
TUNEL-positive cells using the following formula:
Apoptotic index = 100 x (number of TUNEL-positive cells/
number oftotal cell nuclei).
Immunohistochemistry
Immediately after surgery, the tissues were formalin fixed,paraffin
embedded and stained with haematoxylin and eosin.
bcl-2 expression
Paraffin sections (3-5 jim) were dewaxed in xylene and rehy-
drated through graded alcohols. Sections were blocked with 10%
normal rabbit serum for 30 min before adding monoclonal anti-
body against bcl-2 (MAb 124; DBA Italia, Milan, Italy) for 18-24
h at 1:20 dilution. The alkaline phosphatase-antialkaline phos-
phatase (APAAP) method (Cordell et al, 1984) was then used to
amplify the primary antibody signal; the sections were incubated
with rabbit anti-mouse antibody for 30 min, and then with mouse
monoclonal APAAP for another 30 min. These two steps were
then repeated once for 10 min each. The reaction was evidenced
using alkaline phosphatase substrate containing naphthol AS-MX,
fast-red and levamisol (APAAP kits, Dako SpA, Milan, Italy)
yielding an insoluble red reaction product. Sections were counter-
stained with Gill's haematoxylin and then mounted in aqueous
mounting medium. Formalin-fixed, paraffin-embedded sections
from tonsillar tissue were used as positive control. As negative
control, we used PBS instead ofprimary MAb.
p53 and MIBI expression
Sections (3-5 jim) were stained using the avidin-biotin-peroxi-
dase complex (ABC) method. Briefly, dewaxed sections were
treated with 0.3% hydrogen peroxidase in methanol for 30 min to
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Figure 1 TUNEL-positive cell (arrow) in a case of well-differentiated thyroid
carcinoma; original magnification x 300
block the endogenous peroxidase. In order to unmask the p53 and
Ki-67 epitopes, we microwaved the sections in 10 mm citrate
buffer, pH 6.0 (Cattoretti et al, 1992). D-07 (1:200 dilution; Dako
Corporation, Denmark) and MIB-1 (1:100 dilution; Dako) mono-
clonal antibodies were used to study p53 and Ki-67 protein expres-
sion respectively. The sections were then incubated with 1:200
dilution ofbiotin-labelled secondary antibody for 30 min and ABC
(Vector, Burlinghame, CA, USA) for 45 min. Subsequently,
sections were stained for 5 min with 0.05% 3,3-diaminobenzidine
tetrahydrochloride, 0.01% hydrogen peroxide in 0.05 M Tris-HCI
buffer, pH 7.6, counterstained with haematoxylin, dehydrated and
mounted. Negative controls consisted of the replacement of the
primary antibodies with normal mouse serum at the same dilution
as the primary antibodies. Diaminobenzidine-hydrogen peroxi-
dase was used as a chromogen, and a light haematoxylin counter-
stain was used. For negative control, we used PBS instead of the
primary MAb.
Immunohistochemical evaluation
Each section was carefully examined for the presence of nuclear
p53 and MIB-1 immunostaining and for cytoplasmatic bcl-2
immunoreactivity. At least 1000 cells were counted for each case.
The tumours were considered as p53 or bcl-2 positive when at
least 1% ofpositive cells was reactive.
Statistical analysis
The STATISTICA (Stat-Soft) package was used for statistical
analysis and the following tests were employed: (1) Kruskal-Wallis
ANOVA median test; (2) Fisher's exact test; and (3) Spearman
rank correlation. The analysis of survival was performed by the
Kaplan-Meier test.
RESULTS
Apoptosis in thyroid carcinomas
Apoptotic cells contain fragments ofgenomic DNA in their nuclei.
The TUNEL method can detect these cells in situ by labelling the
end of DNA fragments. We used this method to analyse apoptosis
in thyroid tissues by incorporating digoxigenin-conjugated dUTP
into the DNA fragments with the enzyme TdT. As shown in Figure
1, few cells showed positive TUNEL nuclei, which appear dark
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Table 1 Relationship between percentage of MIB-1- positive cells and
histological types of thyroid carcinoma
No. of MIB-1- Apoptotic Ratio
cases positive cells index MIB-1/apoptosi
Histological type Mean ± s.d. Mean ± s.d.
PTC 42 3.1 ±2.9 0.20 ±0.2 15.2
PDC 12 5.6 ± 5.9 0.22 ± 0.3 25.4
UC 21 51.8 23* 1.4 ± 1.2* 37
MC 17 5.1 ±5.3 0.60 ±0.5 8.5
*Fisher's exact test, P<0.01.
Figure 2 MIB-1-positive cells in papillary thyroid carcinoma (arrows); original
magnification x 300
brown. The overall level ofTUNEL-positive cells was very low in
all histotypes analysed. As reported in Table 1, the mean apoptotic
index was 0.20 (s.d. ± 0.2; range 0-0.8) in PTC; 0.22 (s.d. ± 0.2;
range 0-0.8) in PDC; 1.44 (s.d. ± 1.2; range 0-5.2) in UC and 0.6
(s.d. ± 0.5; range 0-1.4) in MC. No apoptotic cells have been
observed in normal thyroid tissues adjacent to carcinomas.
MIB-1 expression in thyroid carcinomas
The mean MIB-1-positive cell rate was significantly different in
thyroid carcinoma subtypes. As reported in Table 1, MIB-1- posi-
tive cell rate was very low in PTC (3.1 ± 2.9), quite high in PDC
(5.6 ± 5.9) and MC (5.1 ± 5.3), and increased significantly (Fisher's
exact test) in UC (51.8 ± 23) (Figure 2).
Figure 3 (A) bcl-2 expression (anti-bcl-2 MAb, APAAP method). Strong bcl-2
immunoreactivity in normal thyroid tissue (arrows); original magnification x
300; (B) undifferentiated area of thyroid carcinoma showing several nuclei of
neoplastic cells immunopositive for p53 protein (original magnification x 400)
Ratio between proliferative activity and apoptotic index
We evaluated the ratio between the percentage of MIB-1 positive
cells and the apoptotic cells in 92 thyroid carcinomas. As expected,
the value of this ratio was significantly higher (Fisher's exact test)
in UC than in the other histotypes (Table 1).
Correlation between bcl-2, p53 and apoptotic index
Table 2 reports the correlation between bcl-2 and p53 protein
expression in 92 thyroid tumours (Figure 3). No association between
Table 2 Correlation between apoptosis index and bcl-2 and p53 expression
Al vs bcl-2 Al vs p53
Bcl-2-positive p53-positive
Histotype cases/total r2 t P cases/total r2 t P
PTC 33/42 0.1 -2.1 0.04 4/42 0.11 2.2 0.02
PDC 12/12 0.05 0.77 NS 1/11 0.008 0.29 NS
UC 6/21 0.09 -1.3 NS 15/21 0.032 -0.79 NS
MC 17/17 0.02 -0.19 NS 1/16 0.14 1.6 NS
Statistical analysis, Kruskal-Wallis ANOVA median test and Spearman rank correlation; NS, not significant.
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bcl-2 protein expression and apoptosis was found in PDC, UC and
MC. Conversely, an inverse correlation (Spearman rank correlation
test, r2 = 0.1; P= 0.04) was present in 42 PTCs. In the same group of
tumours, we also found a direct correlation (Spearman rank correla-
tion test, r2 = 0.11; P = 0.02) between p53 and apoptosis. No statis-
tical significance was present between p53 and apoptotic index in
the other subgroups. In normal thyroid tissues, only a few cells (less
than 1%) were immunoreactive with p53 antibody, while all normal
follicular cells expressed bcl-2.
No significant correlation was observed between apoptosis and
survival age, sex, TNM status and survival (data not shown).
DISCUSSION
Apoptosis plays an important role in developmental biology,
autoimmune disease and tumour growth (Barr and Tomei, 1994).
It is known that, in a tumour a balance between cell proliferation
and apoptotic cell death is a crucial event in its net growth rate
(Williams, 1991). In the present study, we report the percentage of
apoptotic cells in different histotypes of thyroid tumours. In the
same tumours, we also evaluate the proliferative activity by using
the MIB-1 antibody generated againstrecombinantparts ofthe Ki-
67 antigen, which is present inGI, S, G2 and M phases (Cattoretti
et al, 1992). The apoptotic fraction was 0.2 in well-differentiated
papillary thyroid carcinomas as well as in poorly differentiated
carcinomas, 0.6 in medullary carcinoma and 1.4 in undifferenti-
ated tumours. These results suggest that the percentage of apop-
totic cells increases in the more advanced stage of thyroid
tumours. Our results are in agreement with those reported by
Staunton and Gaffney (1995) and Tanimoto et al (1995), who
reported an apoptotic index ranging from 0 to 1.2 in papillary
thyroid carcinoma and a value from 1.9 to 2.9 in anaplastic
subtypes. Taken together, these results suggest that thyroid
neoplastic progression is directly correlated to the increase of
apoptotic index. In contrast to the results that we and others have
obtained in thyroid cancer, Bedi et al (1995) found that the trans-
formation of colorectal epithelium to carcinoma was associated
with a progressive inhibition of apoptosis, although recently
Tatebe et al (1996) have reported that apoptosis occurs more
frequently in metastatic foci than in primary lesions of human
colorectal carcinomas. In neuroblastoma, Gestblom et al (1995)
reported that high density of apoptotic cells indicates favourable
outcome in patients. In contrast, a high apoptotic index seems to
be associated with features of poor prognosis in endometrial
adenocarcinoma (Heatley, 1995). Moreover, in oesophageal squa-
mous cell carcinomas, it has been shown that apoptosis labelling
index increases progressively from cancer localized only in the
mucosa to cancer invading the muscularis propria and/or adven-
titia (Ohbu et al, 1995). These authors paper suggests that single
cell death becomes more frequent as tumour volume increases, a
mechanism which is similar to that ofthe normal epidermis.
Proliferative activity is an important prognostic marker in
several types of cancer (Hofstadter et al, 1995), including thyroid
tumours (Katoh et al, 1995). Several methodologies have been
used to study the growth potential ofneoplastic and non-neoplastic
tissues, i.e. [3H]thymidine autoradiography, measurement ofDNA
content, proliferating cell nuclear antigen (PCNA) and Ki-67
monoclonal antibody. The development of the new monoclonal
antibody, MIB-1, aimed against recombinant parts of the Ki-67
antigen, able to work (in contrast to Ki-67 MAb) in paraffin-
embedded material, allows us to analyse retrospective cases. As
already reported recently (Katoh et al, 1995), well-differentiated
carcinomas (papillary and follicular) have the lowest proliferative
activity, poorly differentiated carcinomas show a medium range of
proliferative cells, while undifferentiated carcinoma present a
significant increase of this 'marker'. Since tumour growth is
affected by both cell proliferation and cell death, we believe the
ratio between these two parameters may be more significant than
the analysis ofthe single marker. The results obtained clearly indi-
cate that this value is more than double in UC than in PTC, and
three times higher in comparison with medullary carcinomas.
Since it is known that apoptosis is regulated by bcl-2 and p53,
we correlated the expression of the protein encoded by these two
genes with the apoptotic index. The bcl-2 proto-oncogene is
shown to confer resistance to apoptotic cell death (Craig, 1995)
and is restricted to the long-lived progenitor cells requiring an
extended life-span (Hockenbery et al, 1991). We and others
(Pollina et al, 1996; Pilotti et al, 1994) have reported recently that
in the thyroid, both from fetal and adult tissue, as well as in differ-
entiated carcinomas, the bcl-2 protein is highly expressed.
Conversely, the expression of the same protein is significantly
reduced in undifferentiated tumours. Since bcl-2 is an antidote to
programmed cell death, we attempt to correlate the bcl-2 protein to
the number of apoptotic cells in the different histotype of thyroid
tumours. We have found that in the PTC group the bcl-2 protein
expression was inversely correlated to percentage of apoptotic
cells, suggesting that the low percentage of apoptotic cells is at
least partly a result ofthe high expression ofbcl-2 protein.
The p53 tumour-suppressor protein is a potent inhibitor of cell
growth and transformation, and is involved in the cellular response
to DNA damage (Merlo et al, 1995). The DNA damage-induced
cell cycle arrest requires wild-type p53 function (Canman et al,
1995). A number ofexperiments have also indicated thatwild-type
p53 can mediate DNA damage-induced programmed cell death,
presumably when the damage is excessive and incompatible with
DNA replication. p53 protein is expressed at very low levels in
differentiated thyroid carcinomas, whereas it is highly expressed
in undifferentiated cancers. Like bcl-2, the expression of p53 is
directly correlated to the apoptotic index only in the papillary form
of thyroid cancer. These data further confirm that p53 is also an
inducer ofPCD in vivo, while bcl-2 is an antidote to cell death.
In conclusion, the present data showed that: (1) both apoptosis
and proliferation are elevated in the more aggressive stage of
thyroid carcinoma, as is the ratio between these two parameters;
(2) bcl-2 is inversely correlated with apoptosis in PTC; (3) p53 is
directly cofrelated to apoptosis; and (4) none of these parameters
are correlated to the outcome in patients.
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